Clinical Trials Logo

Renal Cell Carcinoma Stage IV clinical trials

View clinical trials related to Renal Cell Carcinoma Stage IV.

Filter by:
  • None
  • Page 1

NCT ID: NCT06377722 Terminated - Clinical trials for Renal Cell Carcinoma Metastatic

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC).

NCT ID: NCT05579847 Active, not recruiting - Clinical trials for Renal Cell Carcinoma Stage IV

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Start date: October 19, 2022
Phase:
Study type: Observational

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

NCT ID: NCT04429321 Terminated - Clinical trials for Renal Cell Carcinoma

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Start date: August 26, 2020
Phase: Phase 1
Study type: Interventional

This single center phase 1 trial will study the combination of nivolumab+ipilimumab with embolization in participants with renal cell carcinoma. The study will evaluate the safety of embolotherapy in patients with metastatic RCC receiving nivolumab+ipilimumab. The hypothesis is that the number of serious adverse events will be no greater than the number of serious adverse events for both therapies combined.

NCT ID: NCT04142931 Recruiting - Clinical trials for Triple Negative Breast Cancer

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Start date: February 24, 2020
Phase: Phase 1
Study type: Interventional

Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis system, aiming to answer two different study questions: - Safety, tolerability and effectiveness of the device. - Safety, tolerability and effectiveness of the device, employed as monotherapy, or combined with Nivolumab.